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Abstract: Trachoma is the commonest infectious cause
of blindness worldwide. Recurrent infection of the ocular
surface by Chlamydia trachomatis, the causative agent,
leads to inturning of the eyelashes (trichiasis) and blinding
corneal opacification. Trachoma is endemic in more than
50 countries. It is currently estimated that there are about
1.3 million people blind from the disease and a further 8.2
million have trichiasis. Several estimates for the burden of
disease from trachoma have been made, giving quite
variable results. The variation is partly because different
prevalence data have been used and partly because
different sequelae have been included. The most recent
estimate from the WHO placed it at around 1.3 million
Disability-Adjusted Life Years (DALYs). A key issue in
producing a reliable estimate of the global burden of
trachoma is the limited amount of reliable survey data
from endemic regions.
Introduction
Trachoma is the leading infectious cause of blindness world-
wide. Overall it is the eighth commonest blinding disease [1].
Trachoma is caused by the obligate intracellular bacterium C.
trachomatis. Recurrent episodes of conjunctival infection and the
associated chronic inflammation it causes initiate a scarring
process that ultimately leads to irreversible blindness. There is a
worldwide effort underway to try to control blinding trachoma;
this is lead by the World Health Organization (WHO) with the
Global Alliance for the Elimination of Blinding Trachoma
(GET2020).
It is estimated that approximately 1.3 million people are blind
from this disease and probably a further 1.8 million have low
vision [2]. Trachoma is endemic in more than 50 countries,
predominantly in sub-Saharan Africa, the Middle East, and Asia
[3]. The burden of trachoma on affected individuals and
communities can be huge both in terms of the disability it causes
and the economic costs that result. In this paper we review the
available data on the prevalence of the disease and estimates of its
burden.
Pathogenesis and Clinical Features
Endemic trachoma is caused by the four ocular serovars of C.
trachomatis (A, B, Ba, and C). Although the genital serovars (D to K)
of C. trachomatis can infect the conjunctiva causing either
ophthalmia neonatorum in infants or inclusion conjunctivitis in
adults these are usually isolated episodes for the individual, which
do not lead to blinding sequelae. For endemic trachoma the
average age of acquisition of the first episode of C. trachomatis
infection is probably related to the prevailing level of infection in
the community. In hyperendemic settings infection may be
acquired in early infancy, whereas in meso- and hypo-endemic
regions it is probably on average later. Infection is probably
usually acquired through living in close physical proximity to an
infected person, with the family as the principle unit for
transmission [4,5].
Conjunctival infection with C. trachomatis is largely confined to
the epithelium, with little evidence of deeper spread. The infection
triggers an immune response characterised by a marked
inflammatory cell infiltrate and the release of pro-inflammatory
cytokines in the conjunctiva [6,7]. Clinically it causes papillary
and/or follicular inflammation of the tarsal conjunctiva, referred
to as active trachoma (Figure 1A). The WHO Simplified
Trachoma Grading System (Table 1), which is used by trachoma
control programmes, subdivides active trachoma into two often
coexisting clinical phenotypes: Trachoma Inflammation Follicular
(TF) and Trachoma Inflammation Intense (TI) [8]. Eventually the
infection resolves and the clinically visible inflammation gradually
subsides. Animal models for C. trachomatis infection and limited
data from humans indicate that the resolution of infection is
probably through an interferon-c (IFN-c)–dependent cell-mediat-
ed immune response [9,10]. Studies from trachoma endemic
communities have found that the prevalence and duration of
conjunctival chlamydial infection decline with increasing age,
suggesting that there is a maturation of the immune response as
individuals are repeatedly exposed to infection [11,12]. However,
in the early vaccine trials using whole C. trachomatis organisms the
acquired immunity appeared to be strain specific and relatively
short-lived [13–15]. As a result of the relatively ineffective immune
response, repeated infection of the individual by Chlamydia
trachomatis is common within an endemic environment. This leads
to a recurrent chronic inflammation, which is associated with the
development of scar tissue within the conjunctiva over many years
(Figure 1B) [16,17]. As the scar tissue accumulates it also contracts,
causing the eyelids to roll inwards towards the eye (entropion) and
the eyelashes to scratch the ocular surface (trichiasis, Figure 1C).
The degree to which conjunctival scarring develops probably
depends on a complex interaction between the pressure of
infection (load and frequency) and host specific immunogenetic
factors [18–20]. It is possible that a failure of the immune response
to adequately control the chlamydia leads to prolonged infection
episodes, which provokes more severe inflammation, tissue
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damage (through the release of proteases), and aberrant repair [7].
The most serious disease sequela from trachoma is blinding
corneal opacification (CO, Figure 1D). The main aetiological risk
factor for corneal damage is the presence of trichiasis, however, a
number of other factors probably contribute such as bacterial
infection and chronic conjunctival inflammation [21].
Epidemiology
Today, blinding trachoma is believed to be endemic in 56
countries (Figure 2) [22]. The countries with the highest
prevalence of disease are in sub-Saharan Africa, particularly in
the Sahel belt and East Africa. In addition, there are countries in
the Middle East, the Indian sub-Continent, and Southeast Asia
where trachoma is endemic, although the distribution is patchier.
One hundred years ago trachoma was widespread in Europe and
North America, but faded away during the first half of the 20th
century as living conditions improved [23].
The clinical manifestations of trachoma change with age. Active
trachoma is predominantly seen in young children, becoming less
frequent and shorter in duration with increasing age [11,12].
Conjunctival scarring accumulates with age, usually becoming
evident in the second or third decade of life [24,25]. Entropion,
trichiasis, and CO develop later. The onset of the blinding
complications of trachoma can occur in children living in regions
where the pressure of infection is high [26]. Epidemiological
surveys have generally found trichiasis and CO to be more
common in women than men [25,27]. This difference has been
attributed to the greater life time exposure of women to C.
trachomatis infection, through closer contact with children, the main
reservoir of infection.
The transmission of C. trachomatis from infected to noninfected
individuals is necessary to sustain trachoma in endemic commu-
nities. Several routes of transmission are probably involved
including direct spread (close contact), fomites, and eye-seeking
flies. In common with other Neglected Tropical Diseases (NTDs),
trachoma is generally a disease of resource-poor rural communi-
ties. Risk factors for trachoma are generally things that favour the
transmission of C. trachomatis from one person to another [28]. The
presence of secretions around the eyes has consistently been
associated with active trachoma, attracting flies, and providing a
vehicle for transmission. Similarly, water scarcity probably
promotes transmission, because less water is available to use for
face washing. Limited access to latrines increases faecal contam-
ination of the environment, providing breeding material for the fly
Musca sorbens, which is implicated in trachoma transmission [29].
Crowded living conditions, for example with several young
Figure 1. Clinical features of trachoma. (A) Active trachoma in a child, characterised by a mixed papillary (TI) and follicular response (TF). (B)
Tarsal conjunctival scarring (TS). (C) Entropion and trichiasis (TT). (D) Blinding CO with entropion and trichiasis (TT).
doi:10.1371/journal.pntd.0000460.g001
Author Summary
This review examines the various attempts to estimate the
burden of disease from trachoma, the commonest
infectious cause of blindness worldwide. Reports vary
considerably because of differences in methodology and
changing estimates of the number of people affected.
Currently about 1.3 million are blind from trachoma and it
causes about 1.3 million Disability-Adjusted Life Years
(DALYs). The limited amount of survey data available from
endemic regions remains a problem in generating
accurate estimates. The effect of the disease may be
underestimated as some of the disabling sequelae are not
included in the calculation.
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children sleeping in the same bed, probably promotes transmis-
sion. For many trachoma endemic countries the socioeconomic
developments that might promote the disappearance of the disease
are likely to be very slow in arriving, which in the light of
demographic trends and in the absence of effective control
programmes was predicted to lead to an increase in the total
numbers blind from trachoma [30].
Global Prevalence of Trachoma
Several estimates of the number of people affected by trachoma
worldwide have been made by the WHO and others (Table 2)
[2,3,31–35]. These estimates have generally been produced with
models that have relied on the results of a limited number of
surveys conducted in a few endemic countries. The results have
been extrapolated across these countries and to other countries in
the same region. However, there are problems. The list of
countries included has sometimes been incomplete or contained
countries without endemic trachoma. The survey data used is
sparse, often old, and some of it is of questionable reliability. In the
WHO estimate from the 1990s there was probably a significant
overestimate of the number blind from trachoma (6 million),
because part of the estimate was based on questionnaires reporting
numbers of people who might become blind without treatment
[31,33]. Moreover, there are big gaps. In particular, there are
limited data from both India and China, where pockets of the
disease are thought to exist; even with a low prevalence the
contribution from these two most populous countries could make a
profound difference in the global burden of trachoma. More
recent estimates have been more stringent, using only surveys with
a national sampling frame and the updated WHO list of endemic
countries [33].
However, despite the limitations and potential unreliability of the
available data, there does appear to be an encouraging downward
trend in the numbers (Table 2). The most recent estimate, released
in 2008, suggests that there are currently about 40 million people
with active trachoma and 8.2 million with trichiasis [36]. The
significant downward revision in this estimate was attributed in large
part to significant overestimates in the number of cases in China and
India in the 2004 figures. The highest prevalence of trachoma is
reported from Ethiopia and Sudan, where active trachoma is often
found in more than 50% of children under 10 y, and trichiasis is
found in up to 19% of adults [37,38].
Global Burden of Trachoma
The disabling sequelae of trachoma are visual impairment and
trichiasis. These have a major advantage over the disease sequelae
reported for many other NTDs as they can be readily measured or
observed clinically and do not require special investigations. Visual
impairment is subdivided into Blindness and Low Vision
(Definitions: Box 1). Visual impairment can have a profound
Table 1. The WHO simplified system for the assessment of trachoma [8].
Grade Abbreviation Description
Trachomatous inflammation – follicular TF The presence of five or more follicles (.0.5 mm) in the upper tarsal conjunctiva
Trachomatous inflammation – intense TI Pronounced inflammatory thickening of the tarsal conjunctiva that obscures more
than half of the deep normal vessels
Trachomatous scarring TS The presence of scarring in the tarsal conjunctiva
Trachomatous trichiasis TT At least one lash rubs on the eyeball
Corneal opacity CO Easily visible corneal opacity over the pupil
doi:10.1371/journal.pntd.0000460.t001
Figure 2. Map of trachoma endemic countries in 2009. Reproduced with permission from Silvio P. Mariotti, WHO/NMH/PBD.
doi:10.1371/journal.pntd.0000460.g002
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impact on many aspects of the life of an individual (mobility,
psychological, social, financial, mortality), their family, and the
wider community. Trichiasis can also be disabling in the absence
of visual impairment by causing pain and photophobia. A study
from Tanzania found that women who had trichiasis without
visual impairment suffered a degree of disability that was
comparable to that caused by visual impairment (without
trichiasis) from causes other than trachoma [39]. Moreover, when
both trichiasis and visual impairment are present the degree of
limitation rises to roughly double that of either of these two
elements alone. However, despite the evidence of disability caused
by trichiasis, only one estimate of the burden of disease from
trachoma has included it [40].
The first attempt to calculate the burden of trachoma was in the
Global Burden of Disease study (GBD) [41]. The GBD study
developed a new measure of the burden of disease: Disability-
Adjusted Life Years (DALYs). This measures the gap, in terms of
healthy life lost, between an ‘‘ideal’’ healthy population and the
reality caused by a specific disease in terms of premature mortality
and disability in a particular society. DALYs and the GBD study
have been discussed in detail elsewhere [42]. In essence there are
two major components in the calculation of DALYs: a measure of
premature mortality, years of life lost (YLL); and a measure of
years of healthy life lost through disability caused by the disease,
years of life lived with a disability (YLD). Different disabilities are
weighted so that the more severe the disability the greater the
number of YLDs that are lost. In order to make the calculation it is
necessary to have estimates of the number of people dying from
the disease or living with the disability for a given year.
The GBD study estimated the burden of trachoma to be about
1.0 million DALYs annually, the vast majority of which was due to
YLD (Table 3). This estimate used WHO figures for the number
of people affected by trachoma at that time, which were probably
somewhat less accurate than subsequent estimates, as discussed
above. Moreover, the list of endemic countries used in the process
probably left out some now known to be endemic and included
others where there is not thought to be a problem. Subsequently,
as part of the ongoing updates to the GBD project there have been
further estimations of the burden of trachoma by the WHO
included in the World Health Report using updated estimates for the
global prevalence of the disease (Table 3).
There have been two other calculations of the burden of disease
from Trachoma, in addition to the GBD programme. The first of
these, by Evans and Ranson, was published in 1995 and was an
estimate of the Handicap-Adjusted Life Years (HALYs) for the year
1990 (Table 3) [43]. This measure is similar in concept to the
DALY, consisting of a composite of the number of years lost
through an early death and the number of years lived in a
handicapped state. Instead of using disability weights the authors
developed a new measure, the handicapped weight. The hand-
icapped weights were estimated from self-assessment questionnaires
of people with trachomatous visual impairment. In addition, to
produce this estimate the investigators performed a fresh calculation
for the number of people blind or with low vision from trachoma
worldwide [34]. The value of handicapped weight for blindness they
used was similar to that for DALY calculations (0.58). However, the
value for the low vision handicapped weight (0.59) was higher than
the disability weight for low vision used in other estimates (0.27).
They also performed a sensitivity analysis that found a high degree
of uncertainty around the mean estimate of 79.5 million lifetime
HALYs, with the 95% confidence interval (CI) ranging from 15 to
500 million. This reflects the high degree of uncertainty both in the
estimates of prevalence and other parameters.
The second estimate was made by Frick and colleagues for the
year 2000 (Table 3) [33]. In this calculation the investigators
excluded YLL, because they did not consider its estimate to be
sufficiently reliable. They used a relatively low disability weight for
low vision (0.245). They re-estimated the number of people with
blindness from trachoma worldwide on the basis of a reassessment
of survey data collected since 1980. On the basis of previous
published data they calculated that for each person blinded by
trachoma there were a further 1.4 with low vision, and
extrapolated the number of people with low vision on this basis.
Their estimate of the annual DALYs was 3.6 million, with 72% of
these DALYs occurring within sub-Saharan Africa and 80% of
lifetime DALYs occurring in women. This figure was significantly
higher than the GBD estimate for the same year (2.2 million).
Estimates of the burden of trachoma suffer from several
weaknesses. The first is the limited supply of reliable data on the
prevalence of disease sequelae in endemic populations. There are
relatively few robust population-based surveys that can be used to
estimate the number of affected people. The more recent estimates
of burden have benefited from the work done by the WHO/
GET2020 in defining the list of countries that currently have
endemic trachoma. Secondly, there is uncertainty over whether to
include trichiasis as a disabling disease sequela, independent of
visual impairment. One report has suggested that the additional
disability caused by trichiasis, independent of visual impairment,
may add as much as 50% to the burden of disease caused by
trachoma [40]. Finally, it remains unclear, due to an absence of
data, what degree of premature mortality trachoma-related
Table 2. Estimates of the number of individuals affected by
trachoma worldwide since 1981.
Year Estimated Active Trachoma Trichiasis Blind Low Vision
1981 [32] 500 — 2 —
1990 [34] — — 2.9 3.8
1990 [31] — — 5.9 —
1990 [33] — — 2.8 3.9
1991 [35] 146 10 — —
2000 [33] — — 3.8 5.3
2002 [2] — — 1.3 —
2003 [3] 84 7.6 — —
2008 [36] 40 8.2 — —
Numbers are millions of people.
doi:10.1371/journal.pntd.0000460.t002
Box 1. Definitions of Blindness, Low Vision
and Visual Impairment (International
Statistical Classification of Diseases [ICD-10])
[57].
N Blindness: visual acuity of less than 3/60 (20/400), or a
visual field loss to less than 10u from fixation in the
better eye with best possible correction (ICD-10 visual
impairment categories 3, 4, and 5).
N Low Vision: visual acuity of less than 6/18 (20/60) but
equal to or better than 3/60 in the better eye with best
possible correction (ICD-10 visual impairment categories
1 and 2).
N Visual Impairment: combines both Blindness and Low
Vision (ICD-10 visual impairment categories 1–5).
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blindness may cause. There are two studies from rural commu-
nities in sub-Saharan Africa that have examined the question of
excess mortality due to visual impairment [44,45]. Both of these
found an increase in mortality amongst blind people compared to
sighted controls. As the potential for confounding in assessing
mortality related to visual impairment is high, it is necessary to
conduct carefully designed studies to investigate this question
specifically for trachoma.
Economic Cost of Trachoma
Two estimates of the economic cost of trachoma have been
made by Frick and colleagues [33,40]; these are framed in terms of
lost productivity. The economic cost of one disabled person was
calculated by multiplying the value of the disability weights by the
individual economic productivity value for each country consid-
ered. In the first estimate only the burden caused by visual
impairment was considered and the productivity lost was
estimated at US$ 2.9 billion (1995) [33]. In the second estimate
it was found that the economic loss was higher at US$ 5.3 billion
(2003) [40]. This second estimate used the adjusted dollar value for
2003, it considered the productivity lost from blindness to be
100% (instead of 60%) and it added a 10% cost for each blind
person for a carer. The investigators also examined the effect of
including trichiasis and found that the lost productivity rises
significantly to US$ 8 billion.
There are significant challenges in producing meaningful
estimates of the economic cost of trachoma. Estimates are made
of the cost to the world economy as a whole, rather than the
relative cost to the affected individual. They are greatly influenced
by the per capita GDP of each country involved. A particular
difficulty is determining what average individual productivity value
to use. In the estimates described above the authors used (where
available) the ‘‘average agricultural value added per worker.’’
However, this was not available for each country. It is also
assumed that the affected individual would always be in full-time
paid employment in the absence of their disability and no
adjustment of potential earnings is made for age or sex. It is also
difficult to include a measure for the productivity lost outside the
formal work place or the indirect cost to the carer of a visually
impaired person. Finally there are issues around the choice of
which disabling sequelae to include and the disability weights these
should be given, discussed above.
Trachoma Control and Its Cost-effectiveness
There have been organised trachoma control programmes in
many endemic countries for decades, which have met with
variable success. In 1998 the World Health Assembly resolved to
eliminate blinding trachoma by the year 2020 [46]. To this end
the GET2020 was formed, including representatives from the
WHO, national blindness control programmes from endemic
countries, nongovernmental organisations working in the field,
industry, and academic institutions. The GET2020 alliance
adopted the SAFE Strategy as its favoured approach to controlling
trachoma [47]. The four components of SAFE are surgery for
trichiasis, antibiotics for infection, facial cleanliness, and environ-
mental improvements to reduce transmission.
There is a growing body of published evidence supporting the
clinical effectiveness of each component of the SAFE strategy [48].
In the case of trichiasis surgery there are currently nine published
randomised controlled trials investigating various aspects of
management including the optimal type of operation, level of
surgeon, where surgery should be done, and whether peri-
operative antibiotic improves the outcome [49]. However, there
are major problems both with the outcome of surgery, with high
trichiasis recurrence rates reported under operational conditions,
and the effective delivery of the service on the ground in many
endemic countries [21,50].
Over the last 60 y there have been many studies testing different
antibiotics for active trachoma. The WHO currently recommends
the use of either oral azithromycin (single dose) or topical
tetracycline (twice daily for 6 wk). Both of these antibiotics have
been demonstrated to be effective in clinical trials at reducing the
prevalence of both active disease and C. trachomatis infection [51].
The clinical signs of active trachoma have a relatively low
sensitivity for the identification of C. trachomatis infection. In
addition, C. trachomatis has the potential to rapidly reemerge in
communities where some infected cases are left untreated.
Therefore, the current recommendation is for mass drug
administration (MDA) of entire endemic communities to be
conducted annually for several years, until the prevalence of
follicular trachoma (TF) in children ages 1–9 y drops below 5%
[3]. It is likely that, with such a low threshold for treatment, very
large numbers of uninfected people will be treated with antibiotic
in order to catch all those harbouring infection. The evidence base
supporting the effectiveness of face washing and environmental
interventions in reducing trachoma is more limited [48]. However,
the historical epidemiology of trachoma strongly supports the view
that general improvements in hygiene can have a profound long-
term effect on this disease.
Several investigators have produced estimates of the cost-
effectiveness of trachoma control programmes or individual
components of the SAFE strategy. The only study evaluating the
long-term cost-effectiveness of an entire national trachoma control
Table 3. Estimates of the Global Burden of Trachoma.
Year Source Blindness Cases Low Vision Cases Blindness Weight Low Vision Weight Burden
DALY or HALY n
1990 WDR [41] — — — — DALY 1,024,000
1990 Evans [43] 2.9 3.8 0.58 0.59 Lifetime HALY 79,509,000
2000 Frick [33] 3.8 5.3 0.600 0.245 DALY 3,565,725
2000 Frick [33] 3.8 5.3 0.600 0.245 Lifetime DALY 38,887,187
2002 WHO/GBD [58] 2.9 3.5 0.600 0.278 DALY 2,329,000
2004 WHO/GBD [59] — — 0.600 0.278 DALY 1,334,000
DALYs and HALYs are not directly comparable, as discussed in the text.
doi:10.1371/journal.pntd.0000460.t003
www.plosntds.org 5 October 2009 | Volume 3 | Issue 10 | e460
programme was made by Evans and colleagues for Myanmar
(Burma) over a 30-y period (1964–1993) [52]. This programme
predated the introduction the SAFE strategy; however, it
contained several elements of today’s trachoma control pro-
grammes: surgery, mass antibiotic distribution, and community
education. During this period there was a marked decline in the
disease in Myanmar. The overall cost-effectiveness of the
programme was estimated at US$54 per case of visual impairment
prevented. Two factors may have lead to an overestimate of the
cost-effectiveness: (1) it was assumed that all the visual impairment
from trachoma prevented was due to the activities of the
programme, rather than to any underlying secular trend due to
socioeconomic changes, (2) only the direct costs to the national
programme were included.
Three analyses for the cost-effectiveness of trichiasis surgery
have been produced, which consistently found it to be very cost
effective. In the analysis of the Myanmar programme the average
cost (over the 30-y period) per case of visual impairment prevented
was estimated to be US$193, although in the last 10 y of the
programme there was a marked rise in the cost-effectiveness of
trichiasis surgery to US$41 per case of visual impairment
prevented [52]. The cost per HALY saved was on average
US$10, dropping to US$3 for the final 10 y. In The Gambia the
cost of surgery was estimated to be US$6.13 per operation (1998),
whilst the estimated life-time loss of economic productivity was
US$89 [53]. In a separate analysis the cost-effectiveness of surgery
was estimated for seven trachoma endemic world regions [54].
The cost of trichiasis surgery was estimated to be about
International Dollars (I$) 19 per case in Africa. It was estimated
that if surgery was carried out on 80% of the current cases of
trichiasis this would save 11 million DALYs globally each year.
Surgery was found to be very cost effective with estimates ranging
from I$13 to I$78 per DALY, depending on the region.
The cost-effectiveness of antibiotic treatment has also been
considered in a number of analyses. In the evaluation of the
Myanmar programme it was found that the cost of nonsurgical
interventions (mostly antibiotic treatment) was US$47 per case of
visual impairment prevented [52], which gave a cost-effectiveness
of US$3 per HALY averted. This seems to be a remarkably low
cost and there may have been some major methodological biases
that attributed the vast bulk of the DALYs to the nonsurgical as
opposed to the surgical components of the programme. In
contrast, the more recent projection of the cost-effectiveness of
trachoma control in seven world regions found antibiotic
treatment to be relatively cost ineffective [54]. For example in
Africa the cost of mass antibiotic distribution of azithromycin to
children aged 1–10 y was I$9,012 per DALY saved if the
azithromycin had to be purchased at the standard cost price.
Azithromycin is currently donated by the manufacturer, Pfizer
Inc., to trachoma control programmes in 15 endemic countries.
Even if the drug is donated, the authors concluded that costs
remain high at I$3,922 per DALY. However, this study made a
number of questionable assumptions that cast doubt on these
figure. For example, the authors assumed that mass treatment
would need to be given annually for 10 y, which is probably much
longer than would be needed if high coverage levels are achieved.
The effectiveness of mass azithromycin treatment is variable,
although several studies have suggested that C. trachomatis infection
can be well controlled with one or two rounds of mass treatment
[55,56]. The authors further assumed that the reduction in
trichiasis prevalence due to mass treatment would not be seen for
45 y, and that the proportionate reduction in trichiasis and
blindness would be the same as the reduction in the prevalence of
active trachoma seen after 10 y. It is not known how effective
controlling C. trachomatis infection will be on the development of
the scarring sequelae in people who have previously been
repeatedly infected, however it is anticipated that as the prevalence
of infection drops so the drive to disease progression lessens. There
are major logistical and financial obstacles, even with donated
azithromycin to repeatedly conducting mass drug administration,
especially in remote rural settings. In response to this there has
been a move to try, where appropriate, to combine mass drug
administration with azithromycin for trachoma with treatments for
other NTDs.
Conclusions and Future Directions
Several attempts have been made to estimate both the burden
and cost of trachoma. It remains a significant problem with a high
burden of disability. Encouragingly the reported numbers of
people affected by trachoma appears to be steadily declining.
However, current burden estimates are limited in reliability
because of the paucity of survey data available on which to base
estimates of the total number of cases. There is also variability over
whether to include trichiasis, in the absence of visual impairment.
In order to develop more robust estimates of the burden of
trachoma there needs to be a coordinated effort to conduct
population-based surveys with a national sampling frame in
representative countries from endemic regions. Clarification of the
situation within India and China is particularly important, given
the size of their populations. A consensus also needs to be reached
on whether trichiasis should be included in the calculation of
DALYs and what weight this should be given. There is limited
evidence of premature mortality due to blindness in general.
Further studies on this specifically in relation to trachoma would
be of value.
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